Repositioning Candidate Details
| Candidate ID: | R0140 |
| Source ID: | DB00397 |
| Source Type: | approved; vet_approved; withdrawn |
| Compound Type: | small molecule |
| Compound Name: | Phenylpropanolamine |
| Synonyms: | (+-)-Norephedrine; (+-)-Phenylpropanolamine; Norephedrine; Phenylpropanolamine; PPA |
| Molecular Formula: | C9H13NO |
| SMILES: | CC(N)C(O)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. |
| CAS Number: | 14838-15-4 |
| Molecular Weight: | 151.209 |
| DrugBank Indication: | For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity. |
| DrugBank Pharmacology: | Phenylpropanolamine (PPA), a sympathomimetic agent structurally similar to pseudoephedrine, is used to treat nasal congestion. Phenylpropanolamine is found in appetite suppressant formulations and with guaifenesinin in cough-cold formulations. In 2000, the FDA requested that all drug companies discontinue marketing products containing phenylpropanolamine, due to an increased risk of hemorrhagic stroke in women who used phenylpropanolamine. |
| DrugBank MoA: | Phenylpropanolamine acts directly on alpha- and, to a lesser degree, beta-adrenergic receptors in the mucosa of the respiratory tract. Stimulation of alpha-adrenergic receptors produces vasoconstriction, reduces tissue hyperemia, edema, and nasal congestion, and increases nasal airway patency. PPA indirectly stimulates beta-receptors, producing tachycardia and a positive inotropic effect. |
| Targets: | Dopamine D1 receptor partial agonist; Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist; Alpha-2 adrenergic receptors |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I16 | 6713 | Cerebrovascular disease | An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain. http://en.wikipedia.org/wiki/Cerebrovascular_disease, http://www.ncbi.nlm.nih.gov/books/NBK378/ | disease of anatomical entity/ cardiovascular system disease/ vascular disease/cerebrovascular disease | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |